{
  "company_name": "Rossini S.\u00e0 r.l. (Recordati)",
  "legal_entity": "Rossini SARL",
  "operating_company": "Recordati SpA",
  "alternate_names": [
    "Rossini Investment SARL",
    "Recordati"
  ],
  "sector": "Healthcare - Specialty Pharmaceuticals",
  "geography": "Italy",
  "last_updated": "2026-01-21",
  "data_source": "Debtwire",
  "ratings": {
    "moodys": {
      "rating": "B2",
      "outlook": "Stable"
    },
    "sp": {
      "rating": "NR",
      "outlook": null
    },
    "note": "B2 stable assigned Oct 2018 for acquisition financing. Underlying Recordati is higher quality."
  },
  "overview": {
    "business_description": "Pharmaceutical holding company managing majority stake in Recordati SpA, an Italy-based international specialty pharmaceutical firm. Recordati develops and markets pharmaceuticals for rare diseases and specialty/primary care across Europe and globally. Publicly traded on Milan exchange.",
    "business_positives": [
      "Low distress score of 8 - performing credit",
      "ALL bonds trading ABOVE PAR (101-105)",
      "Underlying Recordati has strong margins and cash generation",
      "Publicly traded operating company provides transparency",
      "Rare disease pharma - high-margin specialty focus",
      "Strong European pharma franchise",
      "CVC sponsorship and operational expertise",
      "Defensive healthcare business model"
    ],
    "fatal_flaw": "Complex corporate structure (holdco debt on operating company equity). Mar 2026 term loan maturity ($47m) approaching. B2 rating reflects structural subordination. CVC exit timing uncertainty.",
    "ownership": "Private - PE-owned. CVC Capital Partners acquired Recordati via Rossini in 2018 for ~$6bn. Recordati remains publicly traded on Milan exchange.",
    "recent_news": "Priced EUR 2bn Sr Secd Notes (Jul 2024). Credit report notes 'complex corporate structure partially mitigated by Recordati's strong margins and cash generation' (Jul 2024)."
  },
  "quick_assessment": {
    "total_debt": 2050,
    "cash_on_hand": null,
    "revolver_available": null,
    "debt_due_one_year": 47,
    "cffo": null,
    "interest_expense": null,
    "ebitda": null,
    "note": "Holdco structure - financials at Recordati level. Strong underlying cash generation."
  },
  "key_ratios": {
    "debt_to_ebitda": null,
    "net_debt_to_ebitda": null,
    "note": "Leverage at Recordati level is conservative. Holdco debt serviced by Recordati dividends."
  },
  "debt_capitalization": [
    {
      "instrument": "Term Loan",
      "amount": 47,
      "maturity": "Mar 2026",
      "coupon": null,
      "price": null,
      "ytw": null,
      "stw": null,
      "rating": "B2",
      "seniority": "Senior Secured",
      "note": "Near-term maturity"
    },
    {
      "instrument": "EUR 850m Sr Secd Notes",
      "amount": 935,
      "maturity": "2029",
      "coupon": null,
      "price": 101.61,
      "ytw": null,
      "stw": null,
      "rating": "B2",
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 1bn Sr Secd Notes",
      "amount": 1100,
      "maturity": "2029",
      "coupon": null,
      "price": 104.57,
      "ytw": null,
      "stw": null,
      "rating": "B2",
      "seniority": "Senior Secured"
    }
  ],
  "maturity_schedule": {
    "year_1": 47,
    "year_2": 0,
    "year_3": 0,
    "year_4": 2035,
    "year_5": 0,
    "thereafter": 0,
    "note": "Small Mar 2026 TL maturity, bulk matures 2029"
  },
  "recent_issuance": [
    {
      "date": "Jul 2024",
      "instrument": "EUR 2bn Sr Secd Notes 2029",
      "pricing": "Market"
    },
    {
      "date": "Oct 2019",
      "instrument": "EUR 650m Sr Secd Notes",
      "pricing": "Market"
    },
    {
      "date": "Dec 2018",
      "instrument": "EUR 850m Sr Secd Notes",
      "pricing": "Market"
    },
    {
      "date": "Oct 2018",
      "instrument": "EUR 1.5bn Sr Secd Notes",
      "pricing": "LBO financing"
    }
  ],
  "underlying_asset": {
    "company": "Recordati SpA",
    "ticker": "REC.MI",
    "exchange": "Milan Stock Exchange",
    "business": "Specialty pharma - rare diseases, specialty care, primary care",
    "geographic_focus": "Europe, with international expansion",
    "strengths": "High margins, strong cash generation, defensive healthcare"
  },
  "transaction_history": {
    "acquisition_date": "2018",
    "acquirer": "CVC Capital Partners",
    "deal_value": 6000,
    "structure": "Holdco LBO - debt at Rossini, equity in Recordati"
  },
  "credit_opinion": {
    "recommendation": "OVERWEIGHT",
    "summary": "Rossini/Recordati is a strong performing credit with low distress score (8) and both bonds trading above par (101-105). While the B2 rating reflects holdco structural subordination, the underlying Recordati is a high-quality specialty pharma with strong margins and cash generation. Credit report specifically notes this mitigates the complex structure. CVC has owned since 2018 - approaching typical PE holding period but no immediate exit pressure given market conditions. Small Mar 2026 TL maturity ($47m) is easily addressable. Healthcare is defensive sector with recurring revenue.",
    "key_risks": [
      "Complex holdco structure - structural subordination",
      "B2 rating despite quality underlying asset",
      "Mar 2026 term loan maturity ($47m)",
      "CVC exit timing uncertainty",
      "Pharma regulatory and pricing risk",
      "Rare disease competition",
      "Italian political/economic risk"
    ],
    "key_catalysts": [
      "Rating upgrade reflecting underlying quality",
      "CVC IPO exit - potential debt reduction",
      "Recordati EBITDA growth",
      "Further spread tightening",
      "M&A upside from Recordati acquisitions"
    ]
  },
  "distress_indicators": {
    "debtwire_distress_score": 8,
    "lifecycle_status": "Performing credit",
    "trading_signals": "All bonds at 101-105 (above par). Strong underlying Recordati cash flows. Low distress score despite holdco structure. Credit quality better than B2 rating implies."
  }
}